Associated Papers
Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4.
Yoo SE et al.
Drug Metabolism and Pharmacokinetics, 2019
Polymorphisms in the carcinogen detoxification genes CYB5A and CYB5R3 and breast cancer risk in African American women.
Blanke KL et al.
Cancer Causes & Control : Ccc, 2014
Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity.
Sacco JC et al.
Pharmacogenetics and Genomics, 2012
Individual variability in the detoxification of carcinogenic arylhydroxylamines in human breast.
Rhoads K et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology, 2011
Cytochrome b5 and NADH cytochrome b5 reductase: genotype-phenotype correlations for hydroxylamine reduction.
Sacco JC et al.
Pharmacogenetics and Genomics, 2010
Discovery and characterization of a cytochrome b5 variant in humans with impaired hydroxylamine reduction capacity.
Kurian JR et al.
Pharmacogenetics and Genomics, 2007
Select a paper to view details